
[Federal Register: February 2, 2010 (Volume 75, Number 21)]
[Notices]               
[Page 5335]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr02fe10-82]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0001]

 
Risk Communication Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Risk Communication Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on February 25, 2010, from 
8 a.m. to 5 p.m. and February 26, 2010, from 8 a.m. to 2 p.m.
    Location: The Hilton Hotel, 8727 Coleville Rd, Silver Spring, MD 
20910
    Contact Person: Lee L. Zwanziger, Office of the Commissioner, rm. 
14-90, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 
20857, 301-827-2895, FAX: 301-827-4050, e-mail: RCAC@fda.hhs.gov, or 
FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 
in the Washington, DC area), code 8732112560. Please call the 
Information Line for up-to-date information on this meeting. A notice 
in the Federal Register about last minute modifications that impact a 
previously announced advisory committee meeting cannot always be 
published quickly enough to provide timely notice. Therefore, you 
should always check the agency's Web site and call the appropriate 
advisory committee hot line/phone line to learn about possible 
modifications before coming to the meeting.
    Agenda: On February 25 and 26, 2010, the committee will discuss 
strategies and lessons from a selection of the FDA's previously issued 
communications, emphasizing communications challenges. Examples, 
selected for illustrative purposes only, will be drawn from 
communications about issues in broad areas such as biologics, drugs, 
medical devices, regulatory actions, and veterinary products. For more 
specific agenda information, please visit the following Web site and 
scroll down to the appropriate advisory committee link (http://
www.fda.gov/AdvisoryCommittees/Calendar/default.htm), or call the FDA 
Advisory Committee Information Line as detailed in the previous 
paragraph. FDA intends to make agenda information available at both 
these locations no later than 15 days before the meeting.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/
default.htm. Scroll down to the appropriate advisory committee link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
February 17, 2010. Oral presentations from the public will be scheduled 
between approximately 1 p.m. and 2 p.m. on February 25, 2010, and 10:30 
to 11:30 a.m. on February 26, 2010. Those desiring to make formal oral 
presentations should notify the contact person and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their presentation 
on or before February 17, 2010. Time allotted for each presentation may 
be limited. If the number of registrants requesting to speak is greater 
than can be reasonably accommodated during the scheduled open public 
hearing session, FDA may conduct a lottery to determine the speakers 
for the scheduled open public hearing session. The contact person will 
notify interested persons regarding their request to speak by February 
18, 2010.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Lee Zwanziger at 
least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/
AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: January 25, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-2053 Filed 2-1-10; 8:45 am]
BILLING CODE 4160-01-S

